Crystal Pharmatech Plans to be the Global Technology Service Leader in Providing Solid State R&D Solutions to Pharmaceutical Companies
Crystal Pharmatech focuses on the specialized field of solid state information for active pharmaceutical ingredients and formulations. Its core services include: salt/polymorph screening, cocrystal screening, chiral resolution, and solid state NMR.
- (1888PressRelease) November 11, 2010 - Crystal Pharmatech Co., Ltd plans to be the global technology service leader in providing solid state R&D solutions to pharmaceutical companies.
"China is currently the top choice for pharmaceutical outsourcing owing to the strong support from government and vast talent pool of relatively low cost labor. There is currently no company in China focused on providing solid state solutions to pharmaceutical companies" explains Alex M. Chen, CEO of Crystal Pharmatech Co., Ltd. "Solid state characterization is critical to speeding up drug development, lowering costs, and providing the highest quality product to innovator pharmaceutical companies. It is inevitable that China-based companies focused on solid state characterization will be an integral component to the outsourcing package."
Besides providing contracted research services, Crystal Pharmatech Co., Ltd, will also be developing new technologies and proprietary devices that will improve efficiency and drive down development costs for all pharmaceutical companies (including generic, outsourcing, and innovators). The plan includes the development of novel mesoporous silica nanoparticles with controllable pore and particle size to be applied to drug delivery, amorphous solid dispersion and/or crystallization.
Crystal Pharmatech Co., Ltd has also entered into collaboration with top research institutes in China such as Peking University, Tsinghua University, Chinese Academy of Sciences, and East China University of Science and Technology.
"With these partnerships, not only do we have access to cutting-edge instrumentation in the fields of solid state characterization and nanotechnology, but we can also work with researchers in applying their knowledge and understanding towards solving complex solid state problems in the pharmaceutical industry."
Crystal Pharmatech Co., Ltd maintains its own capital independently and the company will continue to raise capital through institutional, private equity, and accredited investors.
For more information, visit: http://www.crystalpharmatech.com/
###
space
space
Satisfied Users & 
Approved Press Releases
Print
Email
Report Spam